V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20119558 | 20157758 | 1.75 | 54.8 | Curative (C) | 2019-03-14 | 2019-03-26 | SOTORASIB | N | null | IRINOTECAN + RALTITREXED | 100829071 |
| 20119819 | 20157759 | 1.65 | 42.4 | null | 2018-01-20 | 2018-07-20 | Bortezomib + Daratumumab | 02 | N | ATEZOLIZUMAB | 100531834 |
| 20119905 | 20157760 | 1.84 | 90.8 | Palliative (P) | 2018-05-29 | 2018-07-29 | TISAGENLECLEUCEL-T | 02 | N | ISATUXIMAB + POMALIDOMIDE | 101806113 |
| 20119929 | 20157762 | 1.49 | 62.6 | null | 2021-03-21 | 2021-04-25 | Capital Trial | 02 | null | IPILIMUMAB + NIVOLUMAB | 101496590 |
| 20120501 | 20157765 | 1.46 | 18.1 | Palliative (P) | 2021-08-12 | 2021-09-06 | Cisplatin +FU +Trastuzumab - Load | 02 | null | APALUTAMIDE | 101597204 |
| 20120917 | 20157766 | 1.63 | 71 | Palliative (P) | 2017-06-04 | 2017-06-07 | Vinorelbine (oral) | 02 | N | CYCLOPHOSPHAMIDE + RITUXIMAB | 101524385 |
| 20121101 | 20157767 | 1.8 | 80 | null | 2020-08-30 | 2020-08-31 | TRASTUZUMAB EMTANSINE | 02 | N | CISPLATIN + FLUOROURACIL + RT | 101185358 |
| 20121353 | 20157768 | 1.8 | 68.3 | Palliative (P) | 2019-01-13 | 2019-07-11 | CYCLOPHOSPHAMIDE + ETOPOSIDE | 02 | N | AFATINIB | 100378787 |
| 20121424 | 20157769 | 1.77 | 56.4 | Palliative (P) | 2020-05-12 | 2020-06-02 | Melphalan IV High dose | 02 | N | BEVACIZUMAB + FLUOROURACIL + IRINOTECAN | 100191559 |
| 20121595 | 20157770 | 1.58 | 62.9 | Palliative (P) | 2015-04-15 | 2018-10-07 | Azacitidine | 02 | null | IRINOTECAN + MDG + PANITUMUMAB | 100428743 |
| 20121827 | 20157772 | 1.57 | 133.2 | null | 2021-01-14 | 2021-01-27 | DARATUMUMAB | 02 | N | PHITT | 101766179 |
| 20122070 | 20157773 | 1.46 | 71 | Palliative (P) | 2018-03-05 | 2018-03-05 | Bevacizumab + FLUOROURACIL + IRINOTECAN | 02 | Y | NAB-PACLITAXEL | 101572607 |
| 20122253 | 20157774 | null | 60.2 | Palliative (P) | 2020-04-27 | 2020-04-27 | IRINOTECAN + MDG + PANITUMUMAB | 02 | null | EPIRUBICIN + FLUOROURACIL + OXALIPLATIN | 100911718 |
| 20122409 | 20157775 | 1.81 | 66 | null | 2022-05-22 | 2022-05-24 | MITOMYCIN | 02 | null | BORTEZOMIB | 100193854 |
| 20122467 | 20157776 | 1.75 | 69.1 | Adjuvant (A) | 2018-01-14 | 2018-03-27 | Hydroxycarbamide | 02 | N | AFATINIB | 101785734 |
| 20122584 | 20157777 | 1.47 | 76 | Neo-adjuvant (N) | 2017-09-10 | 2017-10-08 | BCG Intravesical | 02 | null | DOCETAXEL + GEMCITABINE | 100795329 |
| 20122862 | 20157779 | 1.84 | 85.1 | null | 2019-07-21 | 2019-08-10 | PERTUZUMAB + TRASTUZUMAB | 02 | null | CAPITAL TRIAL | 101168979 |
| 20122938 | 20157780 | 1.81 | 101.7 | Curative (C) | 2021-06-27 | 2021-07-12 | CAV | 02 | N | CARBOPLATIN + DOXORUBICIN + MITOMYCIN | 100259335 |
| 20123140 | 20157781 | 1.65 | 95 | Curative (C) | 2018-11-09 | 2019-01-04 | VINORELBINE | 02 | N | TOPOTECAN | 101760433 |
| 20123468 | 20157782 | 1.53 | 109 | Palliative (P) | 2019-11-24 | 2019-12-08 | Topotecan (oral) | 01 | null | CISPLATIN + FLUOROURACIL + TRASTUZUMAB | 100203840 |
| 20123720 | 20157784 | null | null | Palliative (P) | 2019-07-11 | 2020-04-01 | Carboplatin + Raltitrexed | 02 | N | IBRUTINIB | 100302272 |
| 20123749 | 20157785 | 1.84 | 69 | Palliative (P) | 2021-08-25 | 2022-03-07 | Carboplatin + Docetaxel | 2 | null | GEMCITABINE + OXALIPLATIN | 100014955 |
| 20123916 | 20157786 | 1.56 | 91.9 | null | 2016-07-24 | 2016-12-15 | Capecitabine+Cisplatin+Streptozocin | N | N | GEMCITABINE + PACLITAXEL | 100148757 |
| 20123917 | 20157787 | 1.6 | 71 | Palliative (P) | 2018-10-24 | 2018-12-20 | R GDP | 02 | N | HYDROXYCARBAMIDE | 100494997 |
| 20124005 | 20157788 | 0 | 0 | Curative (C) | 2019-08-06 | 2019-08-15 | CAP + RT | 02 | N | BEVACIZUMAB + OXALIPLATIN + MdG | 101570061 |
| 20124035 | 20157789 | 1.65 | 75.3 | Curative (C) | 2019-06-28 | 2019-06-29 | Gemcitabine+Paclitaxel (Neo-tAnGo) | 02 | N | EPIRUBICIN + FLUOROURACIL + OXALIPLATIN | 100810211 |
| 20124045 | 20157790 | 1.83 | 108.1 | Curative (C) | 2018-11-02 | 2018-12-01 | CARBOPLATIN + FLUOROURACIL | 02 | Y | CISPLATIN + GEMCITABINE + RITUXIMAB | 100831046 |
| 20124067 | 20157791 | 1.71 | 66.15 | null | 2018-05-22 | 2018-06-21 | null | 02 | null | STS RHABDOMYOSARCOMA RMS 2005 IVADO | 100017932 |
| 20124087 | 20157792 | 1.8 | 59.4 | null | 2017-11-20 | 2018-05-30 | TRASTUZUMAB EMTANSINE | 02 | null | DABRAFENIB + TRAMETINIB | 100508317 |
| 20124470 | 20157793 | 1.8 | 95 | Neo-adjuvant (N) | 2018-02-26 | 2018-03-16 | Pemetrexed | 02 | N | SCOPE2 TRIAL | 100368605 |
| 20124526 | 20157794 | 1.71 | 64.4 | 03 | 2019-04-18 | 2019-04-19 | Lomustine | 02 | N | BEVACIZUMAB + CAPECITABINE | 100138254 |
| 20124670 | 20157795 | 1.65 | 81 | null | 2021-01-01 | 2021-01-01 | FCarboSt | 02 | null | CARBOPLATIN + PEMETREXED | 100804200 |
| 20124931 | 20157796 | 1.57 | 53 | null | 2020-11-27 | 2020-12-18 | CAPE + OXALIPLATIN + TRASTUZUMAB | 02 | N | IRINOTECAN + RALTITREXED | 101162702 |
| 20125058 | 20157797 | 0 | 0 | Curative (C) | null | 2016-12-23 | DABRAFENIB + TRAMETINIB | 02 | null | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 101523786 |
| 20125466 | 20157799 | 1.57 | 88.4 | Disease modification (D) | 2018-01-20 | 2018-02-17 | Nintedanib | N | null | PHITT C C5VD | 101059715 |
| 20125547 | 20157801 | 1.71 | 52 | Adjuvant (A) | 2016-11-15 | 2016-12-13 | MIC | 02 | N | CAPE + OXALIPLATIN + TRASTUZUMAB | 100696043 |
| 20125581 | 20157802 | 1.71 | 82 | null | 2017-12-20 | 2017-12-22 | Liposomal Doxorubicin 40mg/m2 | 02 | null | IXAZOMIB + LENALIDOMIDE | 101179710 |
| 20125986 | 20157803 | 1.42 | 73.1 | null | 2016-09-01 | 2019-01-23 | CISPLATIN + VINORELBINE + RT | N | Y | BINIMETINIB + ENCORAFENIB | 100261119 |
| 20126178 | 20157805 | null | null | Neo-adjuvant (N) | 2019-07-21 | 2019-07-21 | CAP + RT | 02 | N | FLUOROURACIL + PANITUMUMAB | 101160470 |
| 20126282 | 20157806 | 1.81 | 81.5 | Palliative (P) | 2019-06-20 | 2019-06-21 | Hydroxycarbamide | 02 | null | DARATUMUMAB | 100561003 |
| 20127322 | 20157809 | 1.38 | 92.2 | Palliative (P) | 2020-11-26 | 2021-07-30 | BALLAD Trial | 02 | null | OSIMERTINIB | 100078050 |
| 20127354 | 20157810 | null | null | Curative (C) | 2020-02-11 | 2020-03-26 | Cape +Cetuximab +Oxalip (3 wk)Maint | 02 | N | ATEZOLIZUMAB | 100668601 |
| 20127387 | 20157811 | 1.45 | 78.5 | Palliative (P) | 2020-09-12 | 2020-09-12 | Capital Trial | 02 | N | ATEZOLIZUMAB | 100568877 |
| 20127665 | 20157813 | 1.8 | 71.9 | null | 2018-10-24 | 2018-10-27 | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | N | null | CARBOPLATIN + PEMBROLIZUMAB + PEMETREXED | 100810912 |
| 20128237 | 20157814 | 1.95 | 81.7 | Neo-adjuvant (N) | 2018-09-26 | 2018-09-26 | Melpahan IV Low dose | N | null | CISPLATIN + DOCETAXEL + FLUOROURACIL | 100001782 |
| 20128425 | 20157816 | 1.65 | 69 | null | 2020-12-10 | 2021-01-14 | CHOP - 21 days | 02 | N | DERAZANTINIB | 101186030 |
| 20128598 | 20157817 | 1.79 | 63.4 | null | 2021-01-01 | 2021-01-15 | CHOP R - 21 days | 02 | null | CAPECITABINE + STREPTOZOCIN | 100656961 |
| 20128706 | 20157818 | 1.46 | 103.6 | Palliative (P) | 2017-11-23 | 2017-11-23 | CHOP R - 21 days | null | N | CABOZANTINIB | 101099294 |
| 20128711 | 20157819 | 1.86 | 68.2 | null | 2018-04-07 | 2018-04-14 | CETUXIMAB + RT | 02 | null | STS RHABDOMYOSARCOMA RMS 2005 IVA | 101513469 |
| 20128758 | 20157820 | 1.69 | 55.1 | null | 2020-11-25 | 2020-11-25 | CARBOPLATIN + GEMCITABINE | 02 | null | INTERAACT TRIAL | 100056430 |